RedHill Biopharma (RDHL) to Release Earnings on Thursday

RedHill Biopharma (NASDAQ:RDHLGet Rating) will be issuing its quarterly earnings data before the market opens on Thursday, June 23rd. Analysts expect the company to announce earnings of ($0.40) per share for the quarter.

RedHill Biopharma (NASDAQ:RDHLGet Rating) last posted its earnings results on Thursday, March 17th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.10). RedHill Biopharma had a negative net margin of 113.98% and a negative return on equity of 379.42%. The business had revenue of $22.07 million during the quarter, compared to analyst estimates of $22.99 million. During the same period in the previous year, the firm posted ($0.70) earnings per share. On average, analysts expect RedHill Biopharma to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NASDAQ:RDHL opened at $0.64 on Monday. The company has a current ratio of 1.09, a quick ratio of 0.91 and a debt-to-equity ratio of 9.42. The stock has a market cap of $33.72 million, a price-to-earnings ratio of -0.30 and a beta of 1.93. The stock has a 50-day moving average price of $1.33 and a two-hundred day moving average price of $2.06. RedHill Biopharma has a 1 year low of $0.62 and a 1 year high of $11.18.

Separately, StockNews.com assumed coverage on RedHill Biopharma in a research report on Thursday, March 31st. They set a “hold” rating for the company.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Morgan Stanley raised its stake in RedHill Biopharma by 131.9% in the second quarter. Morgan Stanley now owns 43,694 shares of the biotechnology company’s stock valued at $301,000 after buying an additional 24,855 shares during the period. Wells Fargo & Company MN increased its stake in shares of RedHill Biopharma by 28.8% during the second quarter. Wells Fargo & Company MN now owns 258,018 shares of the biotechnology company’s stock worth $1,776,000 after purchasing an additional 57,718 shares during the period. Cubist Systematic Strategies LLC bought a new position in shares of RedHill Biopharma during the third quarter worth approximately $92,000. UBS Group AG grew its position in RedHill Biopharma by 7.5% during the third quarter. UBS Group AG now owns 100,803 shares of the biotechnology company’s stock worth $462,000 after buying an additional 7,001 shares in the last quarter. Finally, Barclays PLC grew its position in RedHill Biopharma by 956,150.0% during the fourth quarter. Barclays PLC now owns 76,500 shares of the biotechnology company’s stock worth $197,000 after buying an additional 76,492 shares in the last quarter. Institutional investors and hedge funds own 11.08% of the company’s stock.

About RedHill Biopharma (Get Rating)

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.

See Also

Earnings History for RedHill Biopharma (NASDAQ:RDHL)

Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.